A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Epidemiologic studies span an observational-to-experimental spectrum. Cross-sectional surveys capture exposure and disease simultaneously, useful for prevalence but unable to establish temporal order. Cohort studies follow exposed and unexposed groups forward in time to compare incidence. Case-control studies work backward, comparing exposures among those who developed a disease versus those who did not—efficient for rare diseases. Randomized controlled trials assign participants to exposures, eliminating confounding by design and providing the strongest causal evidence. Each design has characteristic strengths, biases, and appropriate use cases.
Use a single disease—such as lung cancer—and trace how you would design a cross-sectional, cohort, case-control, and RCT study around it. Compare the information each yields and identify which biases (selection, recall, confounding) threaten each approach.
Epidemiologists face a fundamental challenge: most of the time, we cannot randomly assign people to harmful exposures or withhold beneficial treatments. We must instead observe what happens in the world. Study designs represent different strategies for drawing causal conclusions from observational data, each with its own logic, strengths, and vulnerabilities.
The simplest design is the cross-sectional survey, which measures exposure and disease status at the same moment. From your prerequisites, you know that cross-sectional studies measure prevalence (existing cases), not incidence (new cases). The core limitation is temporal ambiguity — if smokers have more lung cancer, we cannot tell whether smoking preceded the cancer or whether cancer changed smoking behavior. Cross-sectional studies are useful for generating hypotheses and estimating burden of disease, not for establishing causation.
Cohort studies address the temporal problem by identifying exposed and unexposed groups before disease develops and following them forward. Because exposure precedes outcome by design, you can calculate incidence rates and, from them, the relative risk. The tradeoff: cohort studies require large samples and long follow-up, making them expensive and impractical for rare diseases. A retrospective cohort is a variant where historical records allow you to define exposure groups in the past and trace outcomes forward — same logic, different data source.
Case-control studies flip the design. You start with people who already have the disease (cases) and a comparison group without it (controls), then ask both groups about past exposures. This design is efficient precisely because you recruit based on outcome, not waiting for rare events to accumulate. The cost is that you can never observe incidence rates, so you cannot calculate relative risk directly. Instead, you calculate the odds ratio — the odds of past exposure among cases relative to controls. When the disease is rare, the odds ratio closely approximates the relative risk, which is why the rare disease assumption appears in nearly every case-control paper.
Randomized controlled trials solve what observational studies cannot: they eliminate confounding by design. When participants are randomly assigned to treatment or control, every potential confounder — measured or not — is distributed roughly equally across groups. Any difference in outcomes is then attributable to the treatment. The RCT's weakness is external validity: highly controlled trial populations may not represent real patients, and random assignment is unethical for suspected harmful exposures. This is why RCTs answer "does this treatment work under ideal conditions?" while observational studies answer "what actually happens in the real world?"